Gene Editing Risk-Benefit Framework
Definition
A structured clinical framework for evaluating when gene editing is an appropriate therapeutic strategy versus when existing standard-of-care treatments are superior. Because gene editing carries inherent risks (off-target effects, immunogenicity, irreversibility, mosaicism), the decision to pursue it must be weighed against the performance of available alternatives.
Key Concepts
Framework Criteria for Gene Editing Candidacy
Five criteria determine whether gene editing is clinically justified for a given inherited cardiac condition (sources/gene-editing-cv-tcm-2025 — medium):
- Disease severity — high morbidity and/or mortality if untreated
- Existing therapy effectiveness — standard of care is inadequate or only partially addresses disease
- Monogenic or polygenic architecture — monogenic diseases with a single correctable mutation are most suitable; polygenic diseases are poor candidates
- Somatic delivery feasibility — target tissue accessible by available vectors (e.g., AAV9 for heart)
- Durability and reversibility — therapeutic correction must persist long enough to justify procedural risk; irreversible editing requires high confidence in safety
Paradigm Cases — When Gene Editing is Inappropriate
- WPW syndrome (isolated accessory pathway): Catheter ablation achieves 90–95% long-term success with <2% procedural complications — gene editing risk (off-target mutations, immunogenicity, irreversible genomic change) is disproportionate when a safe, effective, definitive standard therapy exists (sources/gene-editing-cv-tcm-2025)
- Conditions with effective pharmacotherapy — disorders manageable long-term by drugs do not justify the current risk profile of gene editing
Paradigm Cases — When Gene Editing IS Appropriate
- PRKAG2 Cardiac Syndrome: Multisystem monogenic disease (hypertrophy + WPW + glycogen storage + progressive conduction disease); catheter ablation addresses the pathway but cannot reverse the underlying metabolic defect; no effective pharmacological disease modification exists → gene editing is appropriate (sources/gene-editing-cv-tcm-2025; see entities/PRKAG2-Cardiac-Syndrome)
- Homozygous familial hypercholesterolaemia: Despite advanced lipid therapies, residual ASCVD risk remains high; PCSK9 and ANGPTL3 gene editing trials demonstrate durable lipid reduction (sources/gene-editing-cv-tcm-2025)
- TTR amyloidosis: Tafamidis and RNA interference partially address disease; gene editing enabling permanent TTR silencing offers a potentially curative approach that existing agents do not (sources/gene-editing-cv-tcm-2025)
- CPVT (RYR2 GOF): Pharmacological suppression (β-blockers + flecainide) is effective but not curative; direct RYR2 editing or CASQ2 pathway correction targets the root genetic defect with mutation-agnostic potential (sources/gene-editing-cv-tcm-2025; see entities/CPVT)
- DMD cardiomyopathy: No pharmacological disease modification; dystrophin restoration of ~40% in preclinical models improves cardiac architecture and contractility (sources/gene-editing-cv-tcm-2025)
- CALM mutation calmodulinopathy-LQTS: Malignant, difficult-to-treat LQTS variant; CRISPRi suppression of mutant CALM2 normalised electrophysiology in iPSC-CMs (sources/gene-editing-cv-tcm-2025)
Risk Factors That Limit Gene Editing Suitability
- Off-target edits: Potential disruption of essential genes; malignancy risk; proarrhythmic state from unexpected electrophysiological changes (sources/gene-editing-cv-tcm-2025)
- Mosaicism: In vivo cardiac delivery achieves heterogeneous editing across myocardium; >70% phenotypic correction required for cardiac function restoration in mouse models; regions of uncorrected tissue may generate arrhythmia foci or maintain pathogenic phenotype (sources/gene-editing-cv-tcm-2025)
- Immunogenicity: AAV vector immunity limits re-dosing; neoantigen expression from partially edited cells (sources/gene-editing-cv-tcm-2025)
- Irreversibility: Genomic edits are permanent; errors cannot be easily corrected (sources/gene-editing-cv-tcm-2025)
- Human translation gap: Most evidence is from murine models; human myocardium transduction efficiency with AAV9 is not confirmed (sources/gene-editing-cv-tcm-2025)
Contradictions / Open Questions
- No prospective clinical trial has formally validated the framework; all current assessments are extrapolated from preclinical studies and expert consensus
- The 70% mosaicism threshold for cardiac function restoration was demonstrated in mice — the human threshold is unknown and likely differs by condition
- As gene editing safety profiles improve, conditions currently classified as "inappropriate" (e.g., isolated WPW with young patients who relapse) may become appropriate candidates
- How the framework applies to polygenic conditions (e.g., polygenic HCM/DCM) versus monogenic variants of the same phenotype remains unresolved
Connections
- Related to entities/PRKAG2-Cardiac-Syndrome
- Related to entities/CPVT
- Related to entities/ATTR-Amyloidosis
- Related to entities/Familial-Hypercholesterolemia
- Related to concepts/CRISPR-Cas9-in-Channelopathies
- Related to concepts/AAV-Gene-Delivery